29 November 2022: Clinical Research
Sex-Related Differences in Sitagliptin Treatment in Type 2 Diabetes: Results from the PROLOGUE Trial
Xilin Wu 1ABCDEF , Shiming Zhang 1ABCEF , Yingzhu Jin 2ABC , Xun Xiao 3ABCDEF*DOI: 10.12659/MSM.938030
Med Sci Monit 2022; 28:e938030
Table 2 Baseline characteristics of female participants.
| Characteristic | Sitagliptin group | Conventional group | P-value |
|---|---|---|---|
| N | 76 | 69 | |
| Age, years | 71.04±9.10 | 71.35±8.83 | 0.837 |
| Height, cm | 151.23±5.29 | 150.00±5.70 | 0.180 |
| Weight, kg | 57.95±13.62 | 55.62±10.46 | 0.255 |
| Body mass index, kg/m | 25.15±5.03 | 24.82±4.68 | 0.688 |
| Waist circumference, (cm) | 86.97±11.68 | 86.10±11.97 | 0.876 |
| Systolic blood pressure, mmHg | 130.08±14.74 | 130.88±17.76 | 0.766 |
| Diastolic blood pressure, mmHg | 71.26±11.24 | 69.67±11.64 | 0.402 |
| HbA1c,% | 6.58±0.53 | 6.58±0.58 | 0.981 |
| Fasting plasma glucose, mmol/l | 131.49±35.92 | 133.21±41.93 | 0.796 |
| Serum creatinine, μmol/l | 0.71±0.18 | 0.69±0.19 | 0.588 |
| Estimated glomerular filtration rate, ml/min/1.73 m | 66.49±19.09 | 68.78±20.79 | 0.491 |
| Hypertension, N (%) | 60 (78.95%) | 50 (72.46%) | 0.362 |
| Dyslipidemia, N (%) | 58 (76.32%) | 49 (71.01%) | 0.468 |
| Cerebral infarction, N (%) | 10 (13.16%) | 8 (11.59%) | 0.776 |
| Cerebral hemorrhage, N (%) | 1 (1.32%) | 0 (0.00%) | 0.339 |
| Myocardial infarction, N (%) | 7 (9.21%) | 6 (8.70%) | 0.914 |
| Arrhythmia, N (%) | 12 (15.79%) | 7 (10.14%) | 0.314 |
| Chronic heart failure, N (%) | 3 (3.95%) | 7 (10.14%) | 0.141 |
| Percutaneous coronary intervention, N (%) | 13 (17.11%) | 18 (26.09%) | 0.188 |
| Coronary artery bypass grafting, N (%) | 4 (5.26%) | 1 (1.45%) | 0.209 |